Clinical Trial: The Rebound Effect on Repeated Low-Level Red Light Therapy for Myopia

U.S., Aug. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07748546) titled 'The Rebound Effect on Repeated Low-Level Red Light Therapy for Myopia' on July 28.

Brief Summary: Myopia is a global public health issue, projected to affect 49.8% of the world population by 2050, increasing risks of cataracts, glaucoma, macular degeneration, and retinal detachment. Repeated low-level red light (RLRL) therapy has shown promising myopia control in 12-month trials, reducing axial elongation by 69.4% and refractive progression by 76.6% versus spectacles, outperforming 0.01% atropine and benefiting orthokeratology poor responders. However, two-year data indicate declining efficacy in the second year and a rebound effect ...